Logo image of BIO

BIO-RAD LABORATORIES-A (BIO) Stock Price, Forecast & Analysis

USA - New York Stock Exchange - NYSE:BIO - US0905722072 - Common Stock

296.57 USD
-8.65 (-2.83%)
Last: 1/23/2026, 4:15:00 PM
296.57 USD
0 (0%)
After Hours: 1/23/2026, 4:15:00 PM

BIO Key Statistics, Chart & Performance

Key Statistics
Market Cap8.00B
Revenue(TTM)2.56B
Net Income(TTM)-675.90M
Shares26.97M
Float18.32M
52 Week High373.69
52 Week Low211.43
Yearly DividendN/A
Dividend Yield0%
EPS(TTM)10.31
PE28.77
Fwd PE28.79
Earnings (Next)02-11
IPO1980-03-17
Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
BIO short term performance overview.The bars show the price performance of BIO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months 0 5 -5 10 -10

BIO long term performance overview.The bars show the price performance of BIO in the last 1, 2 and 3 years. 1 year 2 years 3 years -10 -20 -30

The current stock price of BIO is 296.57 USD. In the past month the price decreased by -1.48%. In the past year, price decreased by -16.41%.

BIO-RAD LABORATORIES-A / BIO Daily stock chart

BIO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

BIO Fundamental Analysis

ChartMill assigns a fundamental rating of 4 / 10 to BIO. While BIO has a great health rating, its profitability is only average at the moment.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

BIO Financial Highlights

Over the last trailing twelve months BIO reported a non-GAAP Earnings per Share(EPS) of 10.31. The EPS decreased by -1.9% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -6.97%
ROE -10.03%
Debt/Equity 0.18
Chartmill High Growth Momentum
EPS Q2Q%12.44%
Sales Q2Q%0.5%
EPS 1Y (TTM)-1.9%
Revenue 1Y (TTM)-0.88%

BIO Forecast & Estimates

10 analysts have analysed BIO and the average price target is 362.1 USD. This implies a price increase of 22.1% is expected in the next year compared to the current price of 296.57.

For the next year, analysts expect an EPS growth of -2.19% and a revenue growth 0.15% for BIO


Analysts
Analysts76
Price Target362.1 (22.1%)
EPS Next Y-2.19%
Revenue Next Year0.15%

BIO Ownership

Ownership
Inst Owners92.92%
Ins Owners8.18%
Short Float %4.72%
Short Ratio4.92

About BIO

Company Profile

BIO logo image Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company is headquartered in Hercules, California and currently employs 7,700 full-time employees. The firm offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The company operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

Company Info

BIO-RAD LABORATORIES-A

1000 Alfred Nobel Dr

Hercules CALIFORNIA 94547 US

CEO: Norman Schwartz

Employees: 7700

BIO Company Website

BIO Investor Relations

Phone: 15107247000

BIO-RAD LABORATORIES-A / BIO FAQ

What does BIO do?

Bio-Rad Laboratories, Inc. engages in the development and production of specialty chemicals used in biochemical, pharmaceutical, and other life science research applications. The company is headquartered in Hercules, California and currently employs 7,700 full-time employees. The firm offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The company operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.


Can you provide the latest stock price for BIO-RAD LABORATORIES-A?

The current stock price of BIO is 296.57 USD. The price decreased by -2.83% in the last trading session.


Does BIO stock pay dividends?

BIO does not pay a dividend.


How is the ChartMill rating for BIO-RAD LABORATORIES-A?

BIO has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 4 out of 10.


Which stock exchange lists BIO stock?

BIO stock is listed on the New York Stock Exchange exchange.


Can you provide the PE ratio for BIO stock?

The PE ratio for BIO-RAD LABORATORIES-A (BIO) is 28.77. This is based on the reported non-GAAP earnings per share of 10.31 and the current share price of 296.57 USD.


Can you provide the upcoming earnings date for BIO-RAD LABORATORIES-A?

BIO-RAD LABORATORIES-A (BIO) will report earnings on 2026-02-11, after the market close.